Baird Initiates Coverage On PTC Therapeutics With Outperform Rating, Announces Price Target of $44
Baird Initiates Coverage On PTC Therapeutics With Outperform Rating, Announces Price Target of $44
Baird開始跟蹤報道ptc therapeutics,給予跑贏市場評級,目標股價爲44美元
Baird analyst Joel Beatty initiates coverage on PTC Therapeutics (NASDAQ:PTCT) with a Outperform rating and announces Price Target of $44.
Baird 分析師Joel Beatty對ptc therapeutics(納斯達克:PTCT)發起覆蓋,給予超越市場預期的評級,並宣佈目標價爲44美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。